# Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy

> **NCT02795572** · PHASE2 · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 13 (actual)

## Conditions studied

- Peripheral Neuropathy in Breast Cancer Patient

## Interventions

- **DIETARY_SUPPLEMENT:** Vitamin D
- **DIETARY_SUPPLEMENT:** Vitamin B6
- **DIETARY_SUPPLEMENT:** Vitamin B12
- **DIETARY_SUPPLEMENT:** Omega-3 Fatty Acids

## Key facts

- **NCT ID:** NCT02795572
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-27
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Retirement of the Principal Investigator
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795572, "Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02795572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*